ReviewJournal of hematology & oncology2023
How we treat primary immune thrombocytopenia in adults.
Review in Journal of hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07214025 (Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children), which is not on this map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- [Chinese guideline on the diagnosis and treatment of adult primary immune thrombocytopenia (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials.Clinical hematology international · 2025Pooled it
- Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.BMJ (Clinical research ed.) · 2025Trial
- Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.Annals of hematology · 2024Trial
- Persistent Immune Thrombocytopenia as a Post-Acute Sequelae of COVID-19: A Case Report.Public health challenges · 2026Article
- Development of a Machine Learning Algorithm for Differential Diagnosis Between Primary Immune Thrombocytopenia and Connective Tissue Disease-Related Thrombocytopenia in Pediatric Patients.Journal of clinical laboratory analysis · 2026Article
- Article
- MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.British journal of haematology · 2026Review
- Neutrophil-derived S100A8/A9 impairs megakaryocyte maturation in immune thrombocytopenia.Nature communications · 2026Article
- No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study.Global medical genetics · 2026Article
- CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia.Haematologica · 2026Article
- Single-Cell Analysis Highlights Pivotal Role of Eosinophil-Basophil Mast Cell Progenitor-Related Mechanism in Primary Immune Thrombocytopenia.International journal of molecular sciences · 2026Article
- Acute Vaginal Bleeding as the Initial Manifestation of Multifactorial Thrombocytopenia: A Case Report.Cureus · 2026Article
- Thrombocytopenia in Pregnancy: Clinical Challenges, Maternal-Fetal Risks, and Management Strategies.Life (Basel, Switzerland) · 2026Review
- A Comparative Analysis of the Efficacy, Safety and Mechanism of Action of Flebogamma DIF, Fostamatinib and Romiplostim in Immune Thrombocytopenia.Life (Basel, Switzerland) · 2026Review
- Novel use of telitacicept in primary immune thrombocytopenia: a case report.BMC pediatrics · 2026Article
- Immune thrombocytopenia in patients with connective tissue disease.Clinical rheumatology · 2026Review
- The Genetic Link Between Primary Immune Thrombocytopenia and Depression/Anxiety Disorders: A Two-Sample Mendelian Randomization Study.Journal of clinical laboratory analysis · 2026Article
- Regulating effect of genistein on the association of endothelial activation and stress index with atherosclerotic cardiovascular disease risk: a cross-sectional study of the NHANES database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.Journal of clinical medicine · 2026Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Multiple humoral and cellular immune abnormalities result in accelerated platelet destruction and suppressed platelet production in ITP. The diagnosis remains a clinical exclusion of other causes of thrombocytopenia. Treatment is not required except for patients with active bleeding, severe thrombocytopenia, or cases in need of invasive procedures. Corticosteroids, intravenous immunoglobulin, and anti-RhD immunoglobulin are the classical initial treatments for newly diagnosed ITP in adults, but these agents generally cannot induce a long-term response in most patients. Subsequent treatments for patients who fail the initial therapy include thrombopoietic agents, rituximab, fostamatinib, splenectomy, and several older immunosuppressive agents. Other potential therapeutic agents, such as inhibitors of Bruton's tyrosine kinase and neonatal Fc receptor, are currently under clinical evaluation. An optimized treatment strategy should aim at elevating the platelet counts to a safety level with minimal toxicity and improving patient health-related quality of life, and always needs to be tailored to the patients and disease phases. In this review, we address the concepts of adult ITP diagnosis and management and provide a comprehensive overview of current therapeutic strategies under general and specific situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.